San Diego, United States
Replay, founded in 2021 and headquartered in the United States, is carving a niche in the Biotechnology and Health and Wellness sectors. The company's slogan, "Reprogramming biology by writing and delivering big DNA," encapsulates its mission to redefine genomic medicine through innovative genome writing and high-capacity DNA delivery technologies.
Replay has built a comprehensive toolkit that includes a high payload capacity HSV platform, a hypoimmunogenic platform, and a genome writing platform. These technologies target and overcome scientific hurdles hampering clinical advancements in genomic medicine. Employing a hub-and-spoke business model, Replay develops core technologies while its product companies focus on therapeutic applications. Notably, the synHSV™ technology is harnessed to address diseases impacting the skin, eye, brain, and muscle. Additionally, an enzyme writing venture utilizes machine learning to enhance genomic functionality.
The company's recent $55.00M Series A investment on July 25, 2022, featured backers like Axial VC, Lansdowne Partners, and Kohlberg Kravis Roberts, underlining investor confidence in its groundbreaking potential. With leadership composed of distinguished academics and industry veterans, Replay is poised to advance the frontiers of genomic medicine.
